UY25300A1 - Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia - Google Patents
Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotenciaInfo
- Publication number
- UY25300A1 UY25300A1 UY25300A UY25300A UY25300A1 UY 25300 A1 UY25300 A1 UY 25300A1 UY 25300 A UY25300 A UY 25300A UY 25300 A UY25300 A UY 25300A UY 25300 A1 UY25300 A1 UY 25300A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- impotence
- compound
- raises
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invención se refiere al tratamiento de la disfunción eréctil con una combinación de un compuesto seleccionado entre antagonistas de los receptores a-adrenergicos, y un compuesto seleccionado entre los agentes que elevan los niveles de cgmp. se prefiere como elevador de cgmp pde al sildenafilo o una sal farmacéuticamente aceptable del mismo. También se incluyen composiciones y estuches que comprenden tales compuestos para el tratamiento de la impotencia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6974197P | 1997-12-16 | 1997-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25300A1 true UY25300A1 (es) | 2000-12-29 |
Family
ID=22090927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25300A UY25300A1 (es) | 1997-12-16 | 1998-12-14 | Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1037616B1 (es) |
JP (2) | JP2002508315A (es) |
KR (1) | KR20010033092A (es) |
CN (1) | CN1282248A (es) |
AP (1) | AP915A (es) |
AR (1) | AR016433A1 (es) |
AT (1) | ATE318602T1 (es) |
AU (1) | AU759825B2 (es) |
BG (1) | BG104528A (es) |
BR (1) | BR9813699A (es) |
CA (1) | CA2314993A1 (es) |
CO (1) | CO4810381A1 (es) |
CZ (1) | CZ20002199A3 (es) |
DE (1) | DE69833671T2 (es) |
DZ (1) | DZ2675A1 (es) |
EA (1) | EA200000526A1 (es) |
ES (1) | ES2258300T3 (es) |
GT (1) | GT199800177A (es) |
HN (1) | HN1998000174A (es) |
HR (1) | HRP20000407A2 (es) |
HU (1) | HUP0100705A3 (es) |
IL (1) | IL136515A0 (es) |
IS (1) | IS5504A (es) |
MA (1) | MA26586A1 (es) |
NO (1) | NO20003065L (es) |
NZ (1) | NZ504487A (es) |
OA (1) | OA11423A (es) |
PA (1) | PA8462801A1 (es) |
PE (1) | PE20000011A1 (es) |
PL (1) | PL341575A1 (es) |
SK (1) | SK8782000A3 (es) |
TN (1) | TNSN98227A1 (es) |
TR (1) | TR200001733T2 (es) |
UY (1) | UY25300A1 (es) |
WO (1) | WO1999030697A2 (es) |
YU (1) | YU33700A (es) |
ZA (1) | ZA9811507B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DE19844162A1 (de) * | 1998-09-25 | 2000-03-30 | Udo Dunzendorfer | Medikamentenkombinationen zur Therapie der erektilen Dysfunktion |
WO2000053148A2 (en) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Methods and compositions for treating erectile dysfunction |
US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
ES2435816T3 (es) * | 1999-08-03 | 2013-12-23 | Icos Corporation | Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1333824B1 (en) * | 2000-11-17 | 2005-09-07 | Warner-Lambert Company LLC | Treatment of sexual dysfunction with bombesin receptor antagonists |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
CN101781302B (zh) * | 2009-05-31 | 2013-07-10 | 段波 | 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用 |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
CN106233141B (zh) | 2014-02-18 | 2018-08-21 | 罗伯特·I·汉金 | 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA878182B (en) * | 1986-11-05 | 1988-05-02 | Merrell Dow Pharmaceuticals Inc. | Enhancement of prazosin |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
DE69105040T2 (de) * | 1990-05-31 | 1995-03-23 | Pfizer, Inc., New York, N.Y. | Arzneimittel gegen Impotenz. |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
-
1998
- 1998-10-29 HU HU0100705A patent/HUP0100705A3/hu unknown
- 1998-10-29 AT AT98947741T patent/ATE318602T1/de not_active IP Right Cessation
- 1998-10-29 YU YU33700A patent/YU33700A/sh unknown
- 1998-10-29 EA EA200000526A patent/EA200000526A1/ru unknown
- 1998-10-29 CZ CZ20002199A patent/CZ20002199A3/cs unknown
- 1998-10-29 SK SK878-2000A patent/SK8782000A3/sk unknown
- 1998-10-29 JP JP2000538680A patent/JP2002508315A/ja active Pending
- 1998-10-29 EP EP98947741A patent/EP1037616B1/en not_active Revoked
- 1998-10-29 TR TR2000/01733T patent/TR200001733T2/xx unknown
- 1998-10-29 ES ES98947741T patent/ES2258300T3/es not_active Expired - Lifetime
- 1998-10-29 NZ NZ504487A patent/NZ504487A/xx unknown
- 1998-10-29 DE DE69833671T patent/DE69833671T2/de not_active Expired - Fee Related
- 1998-10-29 CA CA002314993A patent/CA2314993A1/en not_active Abandoned
- 1998-10-29 IL IL13651598A patent/IL136515A0/xx unknown
- 1998-10-29 PL PL98341575A patent/PL341575A1/xx unknown
- 1998-10-29 AU AU94558/98A patent/AU759825B2/en not_active Ceased
- 1998-10-29 CN CN98812331A patent/CN1282248A/zh active Pending
- 1998-10-29 WO PCT/IB1998/001723 patent/WO1999030697A2/en active IP Right Grant
- 1998-10-29 KR KR1020007006455A patent/KR20010033092A/ko not_active Application Discontinuation
- 1998-10-29 BR BR9813699-2A patent/BR9813699A/pt not_active Application Discontinuation
- 1998-11-09 GT GT199800177A patent/GT199800177A/es unknown
- 1998-11-10 PA PA19988462801A patent/PA8462801A1/es unknown
- 1998-11-11 HN HN1998000174A patent/HN1998000174A/es unknown
- 1998-11-30 CO CO98070722A patent/CO4810381A1/es unknown
- 1998-12-10 AP APAP/P/1998/001414A patent/AP915A/en active
- 1998-12-11 PE PE1998001206A patent/PE20000011A1/es not_active Application Discontinuation
- 1998-12-14 UY UY25300A patent/UY25300A1/es not_active Application Discontinuation
- 1998-12-15 MA MA25396A patent/MA26586A1/fr unknown
- 1998-12-15 TN TNTNSN98227A patent/TNSN98227A1/fr unknown
- 1998-12-15 AR ARP980106360A patent/AR016433A1/es unknown
- 1998-12-15 DZ DZ980285A patent/DZ2675A1/xx active
- 1998-12-15 ZA ZA9811507A patent/ZA9811507B/xx unknown
-
2000
- 2000-05-19 IS IS5504A patent/IS5504A/is unknown
- 2000-06-13 BG BG104528A patent/BG104528A/xx unknown
- 2000-06-15 NO NO20003065A patent/NO20003065L/no not_active Application Discontinuation
- 2000-06-15 OA OA1200000169A patent/OA11423A/en unknown
- 2000-06-16 HR HR20000407A patent/HRP20000407A2/hr not_active Application Discontinuation
-
2007
- 2007-08-20 JP JP2007213745A patent/JP2007332156A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25300A1 (es) | Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia | |
ES2159839T3 (es) | Derivados del propano, su preparacion y su uso. | |
ES2175350T3 (es) | Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso. | |
CL2018002358A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
PE20020366A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
UY27943A1 (es) | Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos | |
UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
CR7235A (es) | Inhibidores beta- amino tetrahidroimidazol (1,2-a) pirazinas y tetrahidrotrioazolo (4,3-a) pirazinas como depetidil peptidasa para el tratamiento o prevencion de la diabetes | |
UY26482A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
ES2162933T3 (es) | Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft). | |
UY26071A1 (es) | Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp | |
UY27232A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
EP1090644A3 (en) | Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cGMP elevator | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
ECSP982789A (es) | Combinacion eficaz para el tratamiento de la impotencia | |
ES2156889T3 (es) | Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos. | |
PE20040906A1 (es) | Derivados morfolinicos como agonistas de dopamina | |
PE20040868A1 (es) | Nueva combinacion de inhibidor de fosfodiesterasa de tipo 5 (pde5) y antagonista del receptor de angiotensina ii | |
AU3324201A (en) | Tosylproline analogs as thymidylate synthase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20041111 |